S-8 1 d515034ds8.htm S-8 S-8

As filed with the Securities and Exchange Commission on August 2, 2023

Registration No. 333-                

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

Sarepta Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   93-0797222

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification No.)

215 First Street, Suite 415

Cambridge, Massachusetts 02142

(Address of Principal Executive Offices) (Zip Code)

Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan, as amended

(Full title of the plan)

Douglas S. Ingram

President and Chief Executive Officer

Sarepta Therapeutics, Inc.

215 First Street, Suite 415

Cambridge, Massachusetts 02142

(Name and address of agent for service)

(617) 274-4000

(Telephone number, including area code, of agent for service)

Copies to:

Paul M. Kinsella

Ropes & Gray LLP

Prudential Tower

800 Boylston Street

Boston, Massachusetts 02199

(617) 951-7000

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   ☒    Accelerated filer   ☐
Non-accelerated filer   ☐    Smaller reporting company   ☐
     Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

 

 

 

EXPLANATORY NOTE

This Registration Statement on Form S-8 (this “Registration Statement”) is filed to register (i) an additional 2,500,000 shares of common stock, par value $0.0001 per share (“Common Stock”), of Sarepta Therapeutics, Inc. (the “Registrant”) for issuance under the Registrant’s 2018 Equity Incentive Plan, as amended, and (ii) an additional 300,000 shares of Common Stock for issuance under the Registrant’s Amended and Restated 2013 Employee Stock Purchase Plan, as amended and restated on June 27, 2016. This Registration Statement is filed in accordance with General Instruction E to Form S-8 regarding registration of additional securities of the same class, and, pursuant to such instruction, the contents of the Registration Statement on Form S-8 (File No. 333-228719) filed with the Securities and Exchange Commission on December  7, 2018, the contents of the Registration Statement on Form S-8 (File No.  333-240996) filed with the Securities and Exchange Commission on August  5, 2020 and the contents of the Registration Statement on Form S-8 (File No.  333-266461) filed with the Securities and Exchange Commission on August 2, 2022 are each incorporated herein by reference.

Item 8. Exhibits

 

          Incorporated by Reference to Filings
Indicated		  

Exhibit
Number

   

Description

    Form      Exhibit      Filing
Date		      Provided
Herewith		  
    4.1    Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan      10-Q        10.1        8/8/18     
    4.2    Amendment No. 1 to the Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan      8-K        10.1        6/8/20     
    4.3    Amendment No. 2 to the Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan      8-K        10.1        6/3/2022     
    4.4    Amendment No.3 to the Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan      8-K        10.1        6/9/2023     
    4.5    Amended and Restated 2013 Employee Stock Purchase Plan, as amended and restated on June 27, 2016      8-K        10.2        7/1/16     
    4.6    Amendment No.  1 to the Sarepta Therapeutics, Inc. Amended and Restated 2013 Employee Stock Purchase Plan, as amended and restated on June 27, 2016      10-Q        10.4        8/7/19     
    4.7    Amendment No.  2 to the Sarepta Therapeutics, Inc. Amended and Restated 2013 Employee Stock Purchase Plan, as amended and restated on June 27, 2016      8-K        10.1        6/9/2023     
    5.1    Opinion of Ropes & Gray LLP               X  
  23.1    Consent of Ropes & Gray LLP (included in Exhibit 5.1)               X  
  23.2    Consent of KPMG LLP, independent registered public accounting firm               X  
  24.1    Power of Attorney (included in the signature page to this Registration Statement)               X  
107    Filing Fees               X  

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on August 2, 2023.

 

Sarepta Therapeutics, Inc.
By:   /s/ Douglas S. Ingram
  Douglas S. Ingram
  President and Chief Executive Officer

SIGNATURES AND POWERS OF ATTORNEY

Each person whose signature appears below hereby constitutes and appoints Douglas S. Ingram, Ian M. Estepan and Ryan E. Brown, and each of them singly, his or her true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of Sarepta Therapeutics, Inc., and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities indicated below on the dates indicated:

 

Signature    Title   Date

/s/ Douglas S. Ingram

Douglas S. Ingram

    President and Chief Executive Officer, Director
(Principal Executive Officer)		   August 2, 2023

/s/ Ian M. Estepan

Ian M. Estepan

   

Executive Vice President, Chief Financial Officer

(Principal Financial and Accounting Officer)

   August 2, 2023

/s/ M. Kathleen Behrens, Ph.D.

M. Kathleen Behrens, Ph.D.

    Chairwoman of the Board   August 2, 2023

/s/ Richard J. Barry

Richard J. Barry

    Director   August 2, 2023

/s/ Kathryn Boor, Ph.D.

Kathryn Boor, Ph.D.

    Director   August 2, 2023

/s/ Michael Chambers

Michael Chambers

    Director   August 2, 2023

/s/ Stephen L. Mayo, Ph.D.

Stephen L. Mayo, Ph.D.

    Director   August 2, 2023

/s/ Claude Nicaise, M.D.

Claude Nicaise, M.D.

    Director   August 2, 2023

/s/ Hans Wigzell, M.D., Ph.D.

Hans Wigzell, M.D., Ph.D.

    Director   August 2, 2023